GLOPID-R

14/04/2020

COVID-19 Therapeutics Accelerator

GloPID-R members Bill & Melinda Gates Foundation and Wellcome join with Mastercard to facilitate R&D and drug development to tackle COVID-19.

COVID-19 Therapeutics Accelerator

GloPID-R members Bill & Melinda Gates Foundation and Wellcome along with Mastercard have provided $125 million in seed funding to an initiative to accelerate the development of and access to therapies for COVID-19. In their announcement on March 9, 2020, the three organizations stated that the COVID-19 Therapeutics Accelerator was being put in place to help coordinate R&D efforts and remove barriers to drug development and scale-up to address the pandemic.
The funders of the initiative are finalizing processes for accepting and reviewing funding proposals and will release more details as soon as possible. They are also currently seeking additional funding organisations who wish to join the initiative.

For more information on investing in the Therapeutics Accelerator contact: epidemics@wellcome.ac.uk

Learn more about the initiative

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.